EUCTR2022-003365-38-PL招募中1 期
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants with Moderately to Severely Active Crohn’s Disease
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 93
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Men or women, 18 to 75 years of age, inclusive, at the time of consent.
- •2. Capable of giving signed informed consent.
- •3. Documented diagnosis of CD = 3 months prior to Day 1. The diagnosis of CD must be confirmed by clinical, endoscopic, and histologic evidence.
- •4. Moderately to severely active CD.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 13
排除标准
- •1. Current diagnosis of ulcerative colitis, indeterminate colitis, microscopic colitis, ischemic colitis, or infectious colitis.
- •2. Presence of a stoma or ileoanal pouch.
- •3. Presence of currently known complications of CD such as fulminant colitis, toxic megacolon or any other manifestation that may require surgery or hospitalization.
- •4. Known diagnosis of short gut or bowel syndrome.
- •5. Previous exposure to VTX958 or any other TYK2 inhibitor (eg, deucravacitinib) in any study.
研究者
相似试验
进行中（未招募）
1 期
Clinical trial to evaluate the benefit and safety of ST-0529 in subjects who are suffering from active ulcerative colitisActive ulcerative colitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2018-003349-41-DESublimity Therapeutics (Hold Co) Ltd.380
进行中（未招募）
1 期
PaTH Forward: a study to investigate the safety and efficacy of TransCon PTH administered as an injection under the skin daily in adults with hypoparathyroidism.Hypoparathyroidism (HP) in AdultsMedDRA version: 20.0Level: PTClassification code 10021041Term: HypoparathyroidismSystem Organ Class: 10014698 - Endocrine disordersEUCTR2018-004815-33-GBAscendis Pharma Bone Diseases A/S40
进行中（未招募）
1 期
To evaluate the efficacy of M281 injection for the treatment of patients with Myasthenia gravis, a neuromuscular diseaseTreatment of MG, with an initial focus on patients with gMG treated with M281 injection and evaluation of the expected reduce of circulating levels of antibodies by blocking IgG recycling, including the pathogenic autoantibodies that cause MG, and to ameliorate manifestations of the disease.MedDRA version: 20.0Level: PTClassification code 10028417Term: Myasthenia gravisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2018-002247-28-ESMomenta Pharmaceuticals, Inc.68
招募中
1 期
VTX958 for the Treatment of Moderately to Severely Active Crohn’s DiseaseEUCTR2022-003365-38-SKVentyx Biosciences, Inc.93
进行中（未招募）
1 期
VTX958 versus Placebo for the Treatment of Active Psoriatic ArthritisActive Psoriatic ArthritisMedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859EUCTR2022-003056-14-HUVentyx Biosciences, Inc195